Peru Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Peru Pharmaceuticals and Healthcare Report

Peru Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Peru Pharmaceuticals and Healthcare Report
Published Oct 22, 2016
89 pages — Published Oct 22, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

Pharmaceutical foreign direct investment is likely to focus on more advanced and faster-growing markets in the region, such as Brazil and Mexico. Poor intellectual property regulation is a major deterrent to investment and new drug launches. ...Poor intellectual property regulation is a major deterrent to investment and new drug launches. The absence of any comprehensive pricing or reimbursement system leaves multinationals in a weak position against low-cost competitors. Patented medicines are not stocked by public-sector pharmacies. ...Test data exclusivity stipulated by the EU Free Trade Agreement (FTA) may dampen growth in generic drugs. Government failure to contain disease transmission and prevent environmental devastation from oil spills is negatively impacting public health.

...Market conditions for foreign players, as well as importers, should improve as a result of various FTAs. Government support for the generic drugs industry and improvement of regulation should benefit bioequivalent generic drugs manufacturers over the longer term. ...Market conditions for foreign players, as well as importers, should improve as a result of various FTAs. Government support for the generic drugs industry and improvement of regulation should benefit bioequivalent generic drugs manufacturers over the longer term. Foreign retail chains entry should improve supply chains and reduce the presence of unregistered and fake medicines. ...Improvements in price transparency may accelerate generic drugs market growth. Relaxation of biosimilar regulations could provide a welcome boost to Peru s research sector.

...In August ----, the high court of Peru ruled that the health ministry must distribute the morning-after emergency contraception pill at public healthcare clinics across the country, overturning a ---- court decision. The previous ruling allowed the pill to be distributed at private pharmacies but not public hospitals due to doubts over the drug s efficacy. ...

  
Source:
Document ID
1748-2097
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Peru Pharmaceuticals and Healthcare Report" Oct 22, 2016. Alacra Store. Dec 03, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Peru-Pharmaceuticals-and-Healthcare-Report-2026-408>
  
APA:
Business Monitor International - Industry Reports. (2016). Peru Pharmaceuticals and Healthcare Report Oct 22, 2016. New York, NY: Alacra Store. Retrieved Dec 03, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Peru-Pharmaceuticals-and-Healthcare-Report-2026-408>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.